Q32 Bio Sets July 13 for Key Bempikibart Alopecia Data Readout
QTTB has more than doubled off its 52-week low of $1.54.
Summary
Q32 Bio will report 36-week topline results from Part B of its SIGNAL-AA Phase 2a trial of bempikibart in severe alopecia areata on July 13, 2026, with a conference call at 8:00 a.m. ET. This is the first time the company has pinned a specific date for the data, which could validate bempikibart's efficacy and safety in a disease with limited treatment options. The readout follows a $55 million private placement in May and a $300 million shelf registration in June, indicating the company is well-funded to advance the program. Positive results would significantly de-risk the asset and could drive partnership interest or accelerate pivotal plans. The stock, at $11.16 with a $265 million market cap, is highly sensitive to binary clinical events.
At the time of this announcement, QTTB was trading at $11.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $265.5M. The 52-week trading range was $1.54 to $15.02. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: PR Newswire.